摘要
目的观察培美曲赛单药治疗老年晚期非小细胞肺癌(NSCLC)的临床疗效和安全性。方法选取40例局部晚期或转移性NSCLC老年患者为研究对象,给予培美曲赛单药二线或三线化疗,评价客观疗效。观察患者生存时间、无疾病进展生存时间和不良反应发生情况。结果 37例患者可评价客观疗效,有效率为18.92%(7/37),疾病控制率83.78%(31/37)。至随访结束,患者中位生存期10.6个月,中位无疾病进展生存时间4.9个月。常见不良反应包括乏力、贫血和肝功能异常,Ⅲ度不良反应包括贫血2例和乏力4例。结论培美曲赛单药治疗晚期NSCLC老年患者,疾病控制率较好,患者耐受性好。
Objective To observe the clinical efficacy and safety of pemetrexed as mono- therapy fo elderly patients with advanced non-small cell lung cancer (NSCLC). Methods A total of 40 patients with advanced local or metastatic NSCLC were included in this study and received peme- trexed monotherapy as second or third line treatment. The response rate of treatment was evaluated, and the survival time, progression-free survival time and adverse reactions were observed. Results Of 40 cases, 37 cases were available for efficacy evaluation. The overall response rate was 18.92% (7/37) and disease control rate was 83.78% (31/37). The median suvival of all patients was 10.6 months and median progression-free survival time was 4.9 months. The main adverse effects included fatigue, anemia and liver dysfunction. There were 6 cases with 3 grade adverse effects, inclduing 4 cases with fatigue and 2 cases with anemia. Conclusion Findings suggest pemetrexed as monothera- py is potentially well-tolerated and beneficial for elderly patients with advanced NSCLC.
出处
《实用临床医药杂志》
CAS
2016年第23期23-25,共3页
Journal of Clinical Medicine in Practice
基金
中国高校医学期刊临床专项资金(11525990)
关键词
培美曲赛
晚期非小细胞肺癌
老年患者
客观疗效
不良反应
pemetrexed
advanced non-small cell lung cancer
elderly patients
objectiveresponse
adverse effects